Pinto, Leticia C. S.
Mello, Ana P. Q.
Izar, Maria C. O.
Damasceno, Nagila R. T.
Neto, Antonio M. F.
França, Carolina N.
Caixeta, Adriano
Bianco, Henrique T.
Póvoa, Rui M. S.
Moreira, Flavio T.
Bacchin, Amanda S. F.
Fonseca, Francisco A. http://orcid.org/0000-0002-9911-4598
Funding for this research was provided by:
fundação de amparo à pesquisa do estado de são paulo (2012/51692-7)
cnpq (428793/2016-9)
inct-fcx (2014/50983-3)
astrazeneca investigator-initiative grant (ESR 14-10726)
Article History
Received: 3 August 2021
Accepted: 13 September 2021
First Online: 29 September 2021
Declarations
:
: The study protocol was approved by the local ethics committee (Escola Paulista de Medicina – UNIFESP IRB 0297/2014; CAAE: 71652417.3.0000.5505), which follows the latest Declaration of Helsinki, and written informed consent was provided by all patients before their inclusion.
: All authors consented to publish the results shown.
: Dr. FAH Fonseca declares receiving consulting fees from NovoNordisk, Novartis, and AstraZeneca, lecture fees from Novo Nordisk, Abbott, Ache, Biolab, Libbs, Ely Lilly, Sanofi Aventis, Amgen, and AstraZeneca, and travel support from Amgen, Bayer and NovoNordisk. MC Izar declares receiving consulting fees from Amgen, PTC, Amryt Pharma, Novartis, lecture fees from Amgen, PTC, Libbs, Ache, and travel support from Novo Nordisk and Amgen. The authors have no additional relevant financial or nonfinancial interests to disclose.